At a glance
- Originator Novartis
- Class Anti-ischaemics; Antiepileptic drugs; Neuroprotectants; Nootropics
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Craniocerebral trauma; Epilepsy; Stroke